Global ImmuneRepertoire Sequencing Market, By Product Type (Assay Kits (T-Cell ReceptorKits, and B-Cell Receptor Kits) and Instruments), By Application (CancerImmunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Developmentand Efficacy, Transplant Rejection and Tolerance, Infectious Diseases, andOther Applications), By End User (Diagnostic Labs, Biotechnology andPharmaceutical Companies, Academic and Research Institutes, and Others), and ByRegion (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica) was valued at US$ 114.3 millionin 2017, and is projected to exhibit a CAGR of 5.6% over the forecast period(2018 - 2026), as highlighted in a new report published by .
Increasing cancer research,rising government support for pharmacogenomics based drug discovery, and risingnumber of development programs in various therapeutic areas including oncology,cardiology, infectious diseases, psychiatry, pain management, among others aremajor factors expected to drive growth of the immune repertoire sequencingmarket.
Moreover, various organizationsare focusing on developing new solutions to find personalized biomarkers in theimmune system for better and earlier diagnosis of a disease, eventually drivinggrowth of the immune repertoire sequencing market. For instance, in 2013, theHudsonAlpha Institute for Biotechnology, U.S., initiated a project that aims tosequence 10,000 individual’s T-cell repertoire on Illumina HiSeq and B-cellrepertoire on Roche’s 454 GS FLX for diagnosis of several diseases, includingcancers, autoimmune diseases, inflammatory diseases, and infectious diseases.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1517
Manufacturers in the immunerepertoire sequencing market are focusing on strategic mergers and acquisitionsin order to gain significant market share. For instance, in March 2018,ArcherDX Inc. and Ambry Genetics entered into strategic partnership to provideimmune repertoire sequencing services to biopharmaceutical customers. Thispartnership helped both companies to increase its product portfolio in immunerepertoire sequencing segment, globally. Similarly, in January 2018, ThermoFisher Scientific and Illumina, Inc. announced plan for partnership. Thisagreement enables Illumina to sell Ion AmpliSeq technology to researchers whoconduct scientific studies on Illumina’s next-generation sequencing (NGS)platforms.
Browse 38 Market Data Tables and27 Figures spread through 200 Pages and in-depth TOC on "Immune RepertoireSequencing Market, By Product Type (Assay Kits {T-Cell Receptor Kits, andB-Cell Receptor Kits}, and Instruments), By Application (Cancer Immunotherapy,Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy,Transplant Rejection and Tolerance, Infectious Diseases, and OtherApplications), By End User (Diagnostic Labs, Biotechnology and PharmaceuticalCompanies, Academic and Research Institutes, and Others), and By Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa) - GlobalForecast to 2026"
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/immune-repertoire-sequencing-market-1517
Key Takeaways of the ImmuneRepertoire Sequencing Market:
The global immune repertoiresequencing market is expected to expand at a CAGR of 5.6% during the forecastperiod (2018–2026), owing to increasing research & development and demandfor genomic and repertoire sequencing-based research.
Among product type, the assay kitsegment is expected to hold major revenue share in 2026. Various companies arefocusing on collaborations activities to develop immune repertoiresequencing-based kits for certain immunotherapy response, which is expected todrive growth of the assay kits segment in the market. For instance, in April2018, MIODx and DiaCarta entered into an agreement for development of MIODx’sClonoMap immune repertoire sequencing-based tests, to predict patient responseto immunotherapy.
Major players operating in theglobal immune repertoire sequencing market include Thermo Fisher Scientific,Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CDGenomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies,Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1517
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
